PROFILPELAJAR.COM

Fulzerasib

Fulzerasib
Clinical data
Other namesDupert; GFH-925; IBI-351
Legal status
Legal status
Identifiers
  • (7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-7,9-dimethyl-12-(4-methyl-2-propan-2-yl-3-pyridinyl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
FormulaC33H32ClFN6O4
Molar mass631.11 g·mol−1
3D model (JSmol)
  • CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C4=C(C2=O)N(C(=O)[C@@]5(N4CCN(C5)C(=O)C=C)C)C)Cl)C6=C(C=CC=C6F)O
  • InChI=InChI=1S/C33H32ClFN6O4/c1-7-23(43)39-13-14-40-28-19-15-20(34)26(24-21(35)9-8-10-22(24)42)37-30(19)41(27-18(4)11-12-36-25(27)17(2)3)31(44)29(28)38(6)32(45)33(40,5)16-39/h7-12,15,17,42H,1,13-14,16H2,2-6H3/t33-/m1/s1
  • Key:BRWVQEWFJJFLIQ-MGBGTMOVSA-N

Fulzerasib is a drug that is approved in China to treat KRAS G12C-positive non-small cell lung cancer (NSCLC).[2][1][3]

Prior to marketing approval, fulzerasib had received two breakthrough therapy designations, the first for advanced G12C-mutant NSCLC and a second, for colorectal cancer (CRC) from the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration (NMPA).[4]

References

  1. ^ a b Lamb YN (December 2024). "Fulzerasib: First Approval". Drugs. 84 (12): 1665–1671. doi:10.1007/s40265-024-02120-6. PMID 39587006.
  2. ^ "Fulzerasib - GenFleet Therapeutics". AdisInsight. Springer Nature Switzerland AG.
  3. ^ Jiang T, Lin C, Le S, Zhang L, Liang T, Cai L, et al. (August 2025). "Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors". Journal of Medicinal Chemistry. 68 (15) acs.jmedchem.4c03183: 15386–15402. doi:10.1021/acs.jmedchem.4c03183. PMID 40701936.
  4. ^ "Fulzerasib Phase II KROCUS Study | ASCO 2024". DelveInsight Business Research LLP. 2025.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.